New York: The researchers from California Institute of Technology have discovered a new antibody that can make it easier to detect and neutralise HIV virus in an infected patient.
Proteins called broadly neutralising antibodies (bNAbs) are a promising key to prevent infection by HIV — the virus that causes AIDS.
The process of HIV infection begins when the virus comes in contact with human immune cells called T cells that carry a particular protein called CD4 on their surface. Broadly neutralising antibodies have been found in blood samples from some HIV patients whose immune systems can naturally control the infection.
The newly-discovered antibodies may protect a patient’s healthy cells by recognising this protein present on the surface of all HIV strains and inhibiting, or neutralising, the effects of the virus.
“It is actually an advantage if the antibody can recognise different forms,” said Louise Scharf, a postdoctoral scholar.
A potential medical application of this antibody is in combination therapies in which a patient is given a cocktail of several antibodies that work in different ways to fight off the virus as it rapidly changes and evolves.
Scientists have for the first time identified 37 individual types of the human papillomavirus, or HPV, that are specifically linked to human immunodeficiency virus (HIV) infection.
The findings showed that a person with any HPV type, more than one HPV type, or high-risk HPV are more likely to test positive for HIV.
“Although most studies have shown a general link between HPV and HIV co-infection, our findings illustrate the strong relationship between individual HPV types and HIV infection,” said lead author Brandon Brown, Associate Professor at the University of California, Riverside.
“Some HPV types are more linked to cancer and others to warts. This further illustrates the potential utility of HPV vaccine for men who have sex with men and trans women, not only for HPV prevention but also possibly for HIV prevention,” Brown added.
Brown explained that previous research has shown that HPV, in general, was linked to HIV infection, but his research team looked at infection with 37 HPV types and found that individual types are linked, “which is more specific than saying HPV is linked”.
The study, published in the journal PLOS ONE, identified HPV types such as HPV16, 18, 31, 33, 35, 52, 58, linked to HIV.
For the study, the team investigated nearly 600 men who have sex with men, or MSM, and transgender women in Lima, Peru.
Brown and his colleagues started with two groups, one with genital warts and one without, and followed participants over two years to see who contracted HIV.
Of the 571 participants who completed at least two study visits, 73 acquired HIV in two years — a 6 per cent HIV incidence rate.
Previous study with female sex workers showed that the HPV vaccine still provided protection to high-risk groups.
Regarding prevention and treatment, Brown recommends the HPV vaccine, widely provided to everyone regardless of sex, gender, or sexual orientation before sexual debut, and for genital wart treatment.
“Even if the vaccine is not provided before sexual debut, there can be strong benefit if given at any time to prevent HPV-associated disease and also HIV,” he said.
“We know that HPV is the most common STI, and we know that HPV vaccine works to prevent chronic HPV infection. What we need now is to implement the vaccine in a better way. The availability in many other developing countries is low at best and absent at worst.” (IANS)